Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.
A five-gene signature was linked to both event-free survival and overall survival in individuals with a type of rhabdomyosarcoma missing a prognostically informative gene fusion.
MGH runs the clinical fusion assay for all lung cancer patients and the Snapshot NGS test on all patients with solid tumors. It is planning to expand the assays and is also developing a fusion panel for hematological malignancies.
